Blocking PHGDH methylation by a TAT-tagged nonmethylated peptide inhibits HCC growth with no obvious toxicity, suggesting PHGDH methylation might be a therapeutic vulnerability for HCC treatment. This evidence concerns the gene PHGDH and hepatocellular carcinoma.